Foundation Medicine to collaborate with Bristol Myers Squibb on companion diagnostic for solid tumors

Molecular profiling company Foundation Medicine on Tuesday announced a collaboration with Bristol Myers Squibbto develop the FoundationOne CDx test as a companion diagnostic to repotrectinib, Bristol Myers Squibb’s investigational tyrosine kinase inhibitor (TKI).